CNTX · Context Therapeutics Inc.
$0.52
+0.03 (+6.61%)
At close · Aug 20
Market Cap
$43.26M
Shares
91.88M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.52
Open$0.49
Day$0.48–0.52
52W close$0.45–3.36
Avg vol 30d1.9M
Short int5.8M · 6.3% float · 4.2d
Short vol31%
Last earningsJun 15, 2026
DataOct 2021–Aug 2026
Filing10-Q · Aug 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−69%
below
Price vs 50-day avg
−19%
below
RSI (14)
41
neutral
MACD trend
Positive
52-week position
2%
near low
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−77%
trailing
YTD return
−65%
this year
Relative strength
−88%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+32% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.35% of float · ▼ -12.1% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 3-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
EPS growth
+17%
Y/Y
Free cash flow
$-26.4M
Balance sheet
$66.0M
net cash
Quant / Vol
risk profile
Volatility
106%
annualized · 1-yr
Max drawdown
−87%
past year
ATR
10.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−69%
Bearish
Price vs 50-day avg
−19%
Bearish
RSI (14)
41
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+32% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.35% of float · ▼ -12.1% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $1 · 2%
Range high $3
vs 200-day avg -69%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNTX
this stock
Context Therapeutics Inc.
|
$43.26M | -64.6% | — | — | 6.3% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNTX | +2.7% | -12.2% | -76.9% | -13.2% | -64.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +4.7% | -15.5% | -88.1% | -15.3% | -76.5% |
Key facts
CIK
1842952
CUSIP
21077P108
13F (30d)
81 filings
77 filers
Visit website
Investor relations